Recurrent Cystitis Without Prophylaxis
Untreated recurrence repeats several times a year in susceptible patients.
- ≥2/6mo: Definition (or ≥3 episodes per year)
- 2–12/yr: Typical baseline (episodes without prevention)
- Premenopausal: Peak risk group (sexually active women)
- Postmenopausal: Second peak (estrogen-deficiency related)
Why baseline pattern matters for strategy choice
Placeholder: recurrence frequency and trigger pattern guide which prophylaxis strategy fits best.
Placeholder: baseline episode count anchors every comparison in later stages.
Single-Dose Antibiotic After Intercourse
A single antibiotic dose taken after sex targets coitus-triggered infections.
- ~85%: Relative reduction (in coitus-linked recurrence)
- 1 dose: Dosing (within hours of intercourse)
- Coital pattern: Best candidate (clear temporal trigger)
- Lower: Antibiotic exposure (vs. daily continuous dosing)
When post-coital dosing is preferred
Placeholder: post-coital dosing suits patients whose episodes cluster after intercourse.
Placeholder: lower cumulative antibiotic exposure is a key advantage.
Daily Low-Dose Antibiotic Suppression
Daily low-dose antibiotics suppress recurrence regardless of trigger timing.
- ~90%: Relative reduction (across trial durations)
- 3–12 mo: Typical duration (continuous course)
- Non-coital, frequent: Best candidate (unpredictable pattern)
- Resistance risk: Main tradeoff (long-term antibiotic exposure)
Tradeoffs of continuous suppression
Placeholder: continuous prophylaxis trades higher antibiotic exposure for stronger suppression.
Placeholder: adherence and resistance concerns limit long-term continuous use.
Vaginal Estrogen for Postmenopausal Recurrence
Local estrogen therapy targets postmenopausal urogenital tissue changes.
- ~55%: Relative reduction (in postmenopausal recurrence)
- Tissue atrophy: Mechanism target (not antibiotic-based)
- Postmenopausal: Best candidate (estrogen-deficient women)
- None: Antibiotic exposure (non-antibiotic strategy)
Non-antibiotic option for menopausal patients
Placeholder: vaginal estrogen addresses menopause-related recurrence without antibiotics.
Placeholder: well tolerated for long-term local use in menopause.
Choosing Among Prophylaxis Strategies
Strategy choice depends on trigger pattern, menopausal status, and tolerance.
- Coital pattern: Post-coital fit (lowest antibiotic exposure)
- Frequent, non-coital: Continuous fit (strongest suppression)
- Menopausal: Estrogen fit (non-antibiotic option)
- Fewer episodes: Shared goal (balanced against burden)
Matching strategy to patient profile
Placeholder: comparing curves side by side highlights the best-fit strategy per patient.
Placeholder: no single strategy is universally superior across all patients.